Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 6Ovarian Neoplasms 5Colorectal Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Squamous Cell Carcinoma of Head and Neck 3Lymphoma 3Lung Neoplasms 3Head and Neck Neoplasms 3Fallopian Tube Neoplasms 3Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Small Cell Lung Carcinoma 2Neoplasms 2Neoplasm Metastasis 2Endometrial Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Renal Cell 2Carcinoma, Ovarian Epithelial 2Carcinoma, Hepatocellular 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Spinocerebellar Degenerations 1Skin Neoplasms 1Recurrence 1Rectal Neoplasms 1Prostatic Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Microsatellite Instability 1Mesothelioma 1Glioblastoma 1

Interventions

pembrolizumab 3fludarabine 3Cyclophosphamide 3Ipilimumab 2smallpox and monkeypox vaccine modified vaccinia ankara-bavarian nordic 1sargramostim 1reolysin 1poly ICLC 1peginterferon alfa-2a 1osimertinib 1gusacitinib 1fludarabine phosphate 1eprenetapopt 1epacadostat 1dabrafenib 1cobimetinib 1cemiplimab 1Vorinostat 1Temozolomide 1Radiotherapy 1Radiation 1Poly I-C 1Nivolumab 1Monatide (IMS 3015) 1Methods 1MAPRE1 protein, human 1Interleukin-2 1Interleukin-15 1Interleukin-12 1IT-101 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Skin Neoplasms × epacadostat × Clear all
NCT01604889 2026-04-21

A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma

Incyte Corporation

Phase 1/2 Terminated
50 enrolled
Dermatologic

Melanoma, Neoplasms, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡